Catechol-O-Methyltransferase Inhibitors in the Management of Parkinson's Disease

 

 Buy Article Permissions and Reprints

ABSTRACT

Parkinson's disease is the most common neurodegenerative disease in which the chemical pathology is known and effective symptomatic treatment, levodopa, is available. Therapy in the initial years after initiation with dopa decarboxylase inhibitors, carbidopa or benserazide, combined with levodopa results in favorable, stable responses. However, by 5 years after the initiation of treatment, over two thirds of patients experience motor fluctuations beginning initially with a ``wearing-off'' effect followed by more complex fluctuations including dyskinesias and ``on-off'' responses. A number of strategies have been developed in an attempt to deal with these complications including changing doses and frequencies, adding agonist medications, adding or substituting controlled-release levodopa, and surgical therapies. A more recent strategy has centered on increasing the availability of intracellular levodopa and synaptic dopamine by inhibiting the peripheral and central metabolism of levodopa to 3-O-methyldopa with the use of a catechol-O-methyltransferase inhibitor. To date, two of these inhibitors, tolcapone and entacapone, are available to treat the wearing-off phase of levodopa therapy.

REFERENCES

• 1 Brooks D J. PET: its Clinical Role in Neurology.  J Neurol Neurosurg Psychiatry . 1991;  54 1-4
  PubMedGoogle Scholar
• 2 Hornykiewicz O. Biochemical aspects of Parkinson's disease.  Neurology . 1998;  51(suppl. 2) S2-S9
  PubMedGoogle Scholar
• 3 Marsden C D, Parkes D. Success and problems of long-term levodopa therapy in Parkinson's disease.  Lancet . 1977;  1 345-349
  PubMedGoogle Scholar
• 4 Juncos J L. Levodopa: pharmacology, pharmacokinetics and pharmacodynamics.  Neurol Clin . 1992;  10 487-509
  PubMedGoogle Scholar
• 5 Obeso J A, Linazasoro G, Gorospe A. Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain Vol 2. Dopamine Agonists in Early Parkinson's Disease Kent, UK: Wells Medical 1997: 11-35
  Google Scholar
• 6 Kaakkola S, Gordin A, Mannisto P. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase.  Pharmacology . 1994;  25 813-824
  PubMedGoogle Scholar
• 7 DaPrada M, Borgulya J, Napolitano A. Improved therapy of Parkinson's disease with tolcapone and central COMT inhibitors with a S-adenosyl-L-methionine sparing effect.  Clin Neuropharmacol . 1994;  S26-S37 (S26-S37)
  PubMedGoogle Scholar
• 8 Martinez-Martin P, Obrien C. Extending levodopa action: COMT inhibition.  Neurology . 1998;  S27-S32 (S27-S32)
  PubMedGoogle Scholar
• 9 Zurcher G, Dingemane J, DaPrada M. Potent COMT inhibition by RO40-7592 in the periphery and in the brain: preclinical and clinical findings.  Adv Neurol . 1993;  60 641-647
  PubMedGoogle Scholar
• 10 Jorga K. Pharmacokinetics, pharmacodynamics and tolerability of tolcapone: a review of early studies in volunteers.  Neurology . 1998;  S31-S38 (S31-S38)
  PubMedGoogle Scholar
• 11 Waters C, Kurth M, Bailey P. Tolcapone in stable Parkinson's disease: efficacy and safety of long term treatment.  Neurology . 1997;  49 665-671
  PubMedGoogle Scholar
• 12 Rajput A, Martin W, Saint-Hilare M-H. Tolcapone improves motor fluctuation in parkinsonian patients with the ``wearing-off'' phenomena.  Neurology . 1997;  49 1066-1071
  PubMedGoogle Scholar
• 13 Keranen T, Gordin A, Harjolav P. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.  Clin Neuropharmacol . 1993;  16 145-156
  PubMedGoogle Scholar
• 14 Ruottinen H M, Rinne U K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.  J Neurol Neurosurg Psychiatry . 1996;  60 36-40
  PubMedGoogle Scholar
• 15 Rinne U K, Larsen J P, Siden A. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations.  Neurology . 1998;  51 1309-1314
  PubMedGoogle Scholar
• 16 Parkinson's study group. Entacapone improves motor fluctuations in levodopa treated Parkinson's disease patients.  Ann Neurol . 1997;  42 747-755
  CrossrefPubMedGoogle Scholar
• 17 Kurth M, Adler C. COMT inhibition: a new treatment strategy for Parkinson's disease.  Neurology . 1998;  S3-S14 (S3-S14)
  PubMedGoogle Scholar
• 18 Goetz C. Influence of COMT inhibition on levodopa pharmacology and therapy.  Neurology . 1998;  S26-S30 (S26-S30)
  PubMedGoogle Scholar
• 19 Luer R. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.  Pharmacotherapy . 1999;  19 169S-179S
  CrossrefPubMedGoogle Scholar
• 20 Bass H, Beiske A G, Ghika J. Catechol-o-methyltransferase inhibition with tolcapone reduces the ``wearing off'' phenomena and levodopa requirement in fluctuating parkinsonian patients.  J Neurol Neurosurg Psychiatry . 1997;  63 421-428
  PubMedGoogle Scholar